Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniv Med Ctr Utrecht-
Autor(es): dc.contributorUniv Fed Parana-
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorUniversidade do Estado do Rio de Janeiro (UERJ)-
Autor(es): dc.contributorHosp Infantil Albert Sabin-
Autor(es): dc.contributorUniv Florida-
Autor(es): dc.contributorUniversidade Estadual de Campinas (UNICAMP)-
Autor(es): dc.contributorHosp Crianca Brasilia Jose Alencar-
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.contributorUniversidade Federal do Rio de Janeiro (UFRJ)-
Autor(es): dc.contributorHosp Infantil Darcy Vargas-
Autor(es): dc.contributorHosp Estadual Infantil Nossa Senhora da Gloria-
Autor(es): dc.contributorSanta Casa Sao Paulo-
Autor(es): dc.contributorUniversidade Federal da Bahia (UFBA)-
Autor(es): dc.contributorUniversidade Federal de São Paulo (UNIFESP)-
Autor(es): dc.contributorHosp Pequeno Principe-
Autor(es): dc.contributorNatl Inst Publ Hlth & Environm RIVM-
Autor(es): dc.contributorFac Med Barretos FACISB-
Autor(es): dc.creatorRotstein Grein, Ingrid Herta-
Autor(es): dc.creatorPinto, Natalia Ferreira-
Autor(es): dc.creatorLobo, Aline-
Autor(es): dc.creatorGroot, Noortje-
Autor(es): dc.creatorSztajnbok, Flavio-
Autor(es): dc.creatorAlmeida da Silva, Clovis Artur-
Autor(es): dc.creatorPaim Marques, Luciana B.-
Autor(es): dc.creatorAppenzeller, Simone-
Autor(es): dc.creatorIslabao, Aline Garcia-
Autor(es): dc.creatorMagalhaes, Claudia Saad [UNESP]-
Autor(es): dc.creatorAlmeida, Rozana Gasparello de-
Autor(es): dc.creatorBica, Blanca-
Autor(es): dc.creatorFraga, Melissa-
Autor(es): dc.creatorMoreira da Fraga, Aline Coelho-
Autor(es): dc.creatorSantos, Maria Carolina dos-
Autor(es): dc.creatorRobazzi, Teresa-
Autor(es): dc.creatorTerreri, Maria Teresa R. A.-
Autor(es): dc.creatorBandeira, Marcia-
Autor(es): dc.creatorPasmans, Hella-
Autor(es): dc.creatorSchepp, Rutger-
Autor(es): dc.creatorvan der Klis, Fiona-
Autor(es): dc.creatorRoock, Sytze de-
Autor(es): dc.creatorWulffraat, Nico-
Autor(es): dc.creatorPileggi, Gecilmara-
Data de aceite: dc.date.accessioned2022-02-22T00:10:54Z-
Data de disponibilização: dc.date.available2022-02-22T00:10:54Z-
Data de envio: dc.date.issued2020-12-09-
Data de envio: dc.date.issued2020-12-09-
Data de envio: dc.date.issued2020-06-05-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1177/0961203320928406-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/196953-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/196953-
Descrição: dc.descriptionObjective This study aimed to assess the safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccination in childhood-onset systemic lupus erythematosus (cSLE) patients. Methods Volunteer cSLE patients aged 9-20 years and healthy controls (HC) were enrolled to receive a two- or three-dose qHPV vaccination schedule from March 2014 to March 2016. Study visits were performed before the first dose, one month after the second and third doses and one year after the first dose. In each study visit, disease activity and adverse events following vaccination were analyzed, and a serum sample was collected for testing antibody concentrations. Participant recruitment was conducted in 15 Brazilian paediatric rheumatology units. Of the 256 cSLE patients included, 210 completed the two- or three-dose schedules; 15 had previously received one dose, and 18 had received two doses of the vaccine. The analysis was based on intention-to-treat so that participants who did not complete the entire study protocol were also included. Results No severe adverse events were related to the vaccination. Disease activity was generally low and remained stable or even improved. The HC presented 100% seropositivity to HPV16 and HPV18, whereas the two- and three-dose cSLE groups presented 93% and 83% versus 97% and 91%, respectively. One year after the first dose, seropositivity of the three-dose cSLE group was 91% to HPV16 and 84% to HPV18. Conclusions HPV vaccination in cSLE patients is safe and immunogenic. Since the seropositivity to HPV16 and HPV18 was higher for the three-dose schedule group, this regimen should be recommended for cSLE patients.-
Descrição: dc.descriptionUniv Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Paediat Immunol & Rheumatol, Utrecht, Netherlands-
Descrição: dc.descriptionUniv Fed Parana, Hosp Clin, Dept Paediat, Curitiba, Parana, Brazil-
Descrição: dc.descriptionUniv Sao Paulo, Dept Paediat, Fac Med Ribeirao Preto, Sao Paulo, Brazil-
Descrição: dc.descriptionUniv Estado Rio De Janeiro, Dept Paediat Rheumatol, Rio De Janeiro, Brazil-
Descrição: dc.descriptionUniv Sao Paulo, Hosp Clin, Inst Crianca, Dept Paediat Rheumatol,Fac Med, Sao Paulo, Brazil-
Descrição: dc.descriptionHosp Infantil Albert Sabin, Dept Paediat Rheumatol, Fortaleza, Ceara, Brazil-
Descrição: dc.descriptionUniv Florida, Coll Med, Dept Paediat Immunol & Rheumatol, Gainesville, FL USA-
Descrição: dc.descriptionUniv Estadual Campinas, Dept Paediat Rheumatol, Sao Paulo, Brazil-
Descrição: dc.descriptionHosp Crianca Brasilia Jose Alencar, Dept Paediat Rheumatol, Brasilia, DF, Brazil-
Descrição: dc.descriptionUniv Estadual Paulista, Dept Paediat Rheumatol, Botucatu, SP, Brazil-
Descrição: dc.descriptionUniv Fed Rio de Janeiro, Inst Puericultura & Pediat Martagao Gesteira IPPM, Dept Paediat Rheumatol, Rio De Janeiro, Brazil-
Descrição: dc.descriptionUniv Fed Rio de Janeiro, Dept Paediat Rheumatol, Rio De Janeiro, Brazil-
Descrição: dc.descriptionHosp Infantil Darcy Vargas, Dept Paediat Rheumatol, Sao Paulo, Brazil-
Descrição: dc.descriptionHosp Estadual Infantil Nossa Senhora da Gloria, Dept Paediat Rheumatol, Vitoria, ES, Brazil-
Descrição: dc.descriptionSanta Casa Sao Paulo, Dept Paediat Rheumatol, Sao Paulo, Brazil-
Descrição: dc.descriptionUniv Fed Bahia, Dept Paediat Rheumatol, Fac Med, Salvador, BA, Brazil-
Descrição: dc.descriptionUniv Fed Sao Paulo, Dept Paediat Rheumatol, Sao Paulo, Brazil-
Descrição: dc.descriptionHosp Pequeno Principe, Dept Paediat Rheumatol, Curitiba, Parana, Brazil-
Descrição: dc.descriptionNatl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands-
Descrição: dc.descriptionFac Med Barretos FACISB, Dept Paediat Rheumatol, Barretos, Brazil-
Descrição: dc.descriptionUniv Estadual Paulista, Dept Paediat Rheumatol, Botucatu, SP, Brazil-
Formato: dc.format934-942-
Idioma: dc.languageen-
Publicador: dc.publisherSage Publications Ltd-
Relação: dc.relationLupus-
???dc.source???: dc.sourceWeb of Science-
Palavras-chave: dc.subjectSystemic lupus erythematosus-
Palavras-chave: dc.subjectautoimmune diseases-
Palavras-chave: dc.subjectvaccination-
Palavras-chave: dc.subjectdisease activity-
Título: dc.titleSafety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.